Overview
The goal of this observational study is to learn about the treatment effectiveness of physician's choice of chemotherapy and the immune checkpoint inhibitor (ICI)-based therapy in patients with relapsed/refractory ovarian clear cell carcinoma (OCCC), and compare the treatment response with the phase II, single-arm clinical trial INOVA to investigate the efficacy of combinational therapy of sintilimab plus bevacizumab. The main questions it aims to answer are:
- What is the efficacy of physician's choice of chemotherapy in relapsed/refractory OCCC patients in the real world?
- Is ICI-based therapy more effective than physician's choice of chemotherapy in real-world for relapsed/refractory OCCC patients?
- Dose the combinational regimens of sintilimab plus bevacizumab in Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA) trial more effective than physician's choice of chemotherapy?
Participants will be respectively retrieved and extracted de-identified, longitudinal electronic health records (EHR)-derived data.
Eligibility
Inclusion Criteria:
- Female patients with age ≥ 18 years old and ≤ 75 years old.
- There must be a histological diagnosis of ovarian clear cell carcinoma.
- Patients with recurrent or persistent ovarian clear cell carcinoma must have at least one-line pretreated platinum-containing chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2.
- Expected survival time ≥ 12 weeks.
Exclusion Criteria:
1.Histological evidence of non-ovarian clear cell carcinoma.